The influence of tobacco smoking on adhesion molecule profiles
DA Scott 1  
More details
Hide details
Department of Oral Biology, University of Manitoba, Canada
Department of Periodontology and Preventive Dentistry, King’s College London, UK
Publish date: 2002-01-15
Tobacco Induced Diseases 2003;1(January):7
Sequential interactions between several adhesion molecules and their ligands regulate lymphocyte circulation and leukocyte recruitment to inflammatory foci. Adhesion molecules are, therefore, central and critical components of the immune and inflammatory system. We review the evidence that tobacco smoking dysregulates specific components of the adhesion cascade, which may be a common factor in several smoking-induced diseases. Smoking causes inappropriate leukocyte activation, leukocyte-endothelial adhesion, and neutrophil entrapment in the microvasculature, which may help initiate local tissue destruction. Appropriate inflammatory reactions may thus be compromised. In addition to smoke-induced alterations to membrane bound endothelial and leukocyte adhesion molecule expression, which may help explain the above phenomena, smoking has a profound influence on circulating adhesion molecule profiles, most notably sICAM-1 and specific sCD44 variants. Elevated concentrations of soluble adhesion molecules may simply reflect ongoing inflammatory processes. However, increasing evidence suggests that specific soluble adhesion molecules are immunomodulatory, and that alterations to soluble adhesion molecule profiles may represent a significant risk factor for several diverse diseases. This evidence is discussed herein.
DA Scott   
Department of Oral Biology, Faculty of Dentistry, University of Manitoba, 780 Bannatyne Ave, Winnipeg, MB, R3E 0W2, Canada
1. Corre F, Lellouch J, Schwartz D: Smoking and leucocytecounts. Results of an epidemiological survey. Lancet. 1971, 2 (7725): 632-634.
2. Finkelstein EI, Nardini M, Vliet van der A: Inhibition of neutrophil apoptosis by acrolein: a mechanism of tobacco-related lung disease?. American Journal of Physiology. 2001, 281: L732-739.
3. Hughes DA, Haslam PL, Townsend PJ, Turner-Warwick M: Numerical and functional alteration in circulatory lymphocytes in cigarette smokers. Clinical and Experimental Immunology. 1985, 61: 459-466.
4. Pitzer JE, Del Zoppo GJ, Schmid-Schonbein GW: Neutrophil activation in smokers. Biorheology. 1996, 33: 45-58.
5. Schwartz J, Weiss ST: Cigarette smoking and peripheral blood leukocyte differentials. Annals of Epidemiology. 1994, 4: 236-242.
6. Tanigawa T, Araki S, Nakata A, Sakurai S: Increase in the helper inducer (CD4+CD29+) T lymphocytes in smokers. Industrial Health. 1998, 36: 78-81.
7. van Eeden SF, Hogg JC: The response of human bone marrow to chronic cigarette smoking. European Respiratory Journal. 2000, 15: 915-921.
8. Bahna SL, Heiner DC, Myhre BA: Changes in serum IgD in cigarette smokers. Clinical and Experimental Immunology. 1983, 51: 624-630.
9. Bahna SL, Heiner DC, Myrhe BA: Immunoglobulin E pattern in cigarette smokers. Journal of Allergy and Clinical Immunology. 1983, 38: 57-64.
10. Burrows B, Halonen M, Barbee RA, Lebowitx MD: The relationship of serum IgE to cigarette smoking. American Reviews in Respiratory Disease. 1981, 124: 523-525.
11. Gunsolley JC, Pandey JP, Quinn SM, Tew J, Schenkein HA: The effect of race, smoking and immunoglobulin allotypes on IgG subclass concentrations. Journal of Periodontal Research. 1997, 32: 381-387.
12. Geng Y, Savage SM, Johnson LJ, Seagrave J, Sopori ML: Effects of nicotine on the immune response. I. Chronic exposure to nicotine impairs antigen receptor-mediated signal transduction in lymphocytes. Toxicology and Applied Pharmacology. 1995, 135: 268-278.
13. Geng Y, Savage SM, Razani-Boroujerdi S, Sopori ML: Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy. Journal of Immunology. 1996, 156: 2384-2390.
14. Sopori ML, Kozak W: Immunomodulatory effects of cigarette smoke. Journal of Neuroimmunology. 1998, 83: 148-156.
15. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE: Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. New England Journal of Medicine. 1996, 334: 150-154.
16. Ernst E: Haemorheological consequences of chronic cigarette smoking. Journal of Cardiovascular Risk. 1995, 2: 435-439.
17. Meekin TN, Wilson RF, Scott DA, Ide M, Palmer RM: Laser Doppler flowmeter measurement of relative gingival and forehead skin blood flow in light and heavy smokers during and after smoking. Journal of Clinical Periodontology. 2000, 27: 236-242.
18. Rezavandi K, Palmer RM, Odell EW, Scott DA, Wilson RF: Expression of E-Selectin and ICAM-1 in gingival tissues of smokers and non-smokers with periodontitis. Journal of Oral Pathology and Medicine. 2002, 31: 59-64.
19. Smith CJ, Fischer TH: Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis. 2001, 158: 257-267.
20. Koethe SM, Kuhnmuench JR, Becker CG: Neutrophil priming by cigarette smoke condensate and a tobacco anti-idiotypic antibody. American Journal of Pathology. 2000, 157: 1735-1743.
21. Zapolska-Downar D, Naruszewicz M, Zapolski-Downar A, Markiewski M, Bukowska H, Millo B: Ibuprofen inhibits adhesiveness of monocytes to endothelium and reduces cellular oxidative stress in smokers and non-smokers. European Journal of Clinical Investigation. 2000, 30: 1002-1010.
22. Nair S, Kulkarni S, Camoens HM, Ghosh K, Mohanty D: Changes in platelet glycoprotein receptors after smoking – a flow cytometric study. Platelets. 2001, 12: 20-26.
23. Kuschner WG, D'Alessandro A, Wong H, Blanc PD: Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. European Respiratory Journal. 1996, 9: 1989-1994.
24. Tappia PS, Troughton KL, Langley-Evans SC, Grimble RF: Cigarette smoking influences cytokine production and antioxidant defense. Clinical Science. 1995, 88: 485-489.
25. Barbour SE, Nakashima K, Zhang JB, Tangada S, Hahn CL, Schenkein HA, Tew JG: Tobacco and smoking: environmental factors that modify the host response (immune system) and have an impact on periodontal health. Critical Reviews in Oral Biology and Medicine. 1997, 8: 437-460.
26. Lehr HA: Microcirculatory dysfunction induced by cigarette smoking. Microcirculation. 2000, 7: 367-384.
27. Díaz-González F, Sánchez-Madrid F: Inhibition of leukocyte adhesion: an alternative mechanism of action for anti-inflammatory drugs. Immunology Today. 1998, 19: 169-172.
28. Gearing AJH, Newman W: Circulating adhesion molecules in disease. Immunology Today. 1994, 14: 506-512.
29. Johnson P, Maiti A, Brown KL, Li R: A role for the cell adhesion molecule CD44 and sulfation in leukocyte-endothelial cell adhesion during an inflammatory response?. Biochemical Pharmacology. 2000, 59: 455-465.
30. Johnson-Léger C, Aurraund-Lions M, Imhof BA: The parting of the endothelium: miracle, or simply a junctional affair?. Journal of Cell Science. 2000, 113: 921-933.
31. Muller WA, Weigl SA, Deng X, Phillips DM: PECAM-1 is required for transendothelial migration of leukocytes. Journal of Experimental Medicine. 1993, 178: 449-460.
32. Shen Y, Rattan V, Sultana C, Kalra VK: Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes. American Journal of Physiology. 1996, 270: H1624-1633.
33. Vaporciyan AA, DeLisser HM, Yan HC, Mendiguren II, Thom SR, Jones ML, Ward PA, Albelda SM: Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science. 1993, 262: 1580-1582.
34. Cuff CA, Kothapalli D, Azonobi I, Chun S, Zhang Y, Belkin R, Yeh C, Secreto A, Assoian RK, Rader DJ, Pure E: The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. Journal of Clinical Investigation. 2001, 108: 1031-1040.
35. Etzioni A, Doerschuk CM, Harlan JM: Of mice and men: leukocyte and adhesion molecule deficiencies. Blood. 1999, 94: 3281-3288.
36. Hellewell PG: Adhesion molecule strategies. Pulmonary Pharmacology and Therapeutics. 1999, 12: 137-141.
37. Hubbard AK, Rothlein R: Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radical Biology and Medicine. 2000, 28: 1379-1386.
38. Prosper F, Verfaille CM: Regulation of hematopoiesis through adhesion receptors. Journal of Leukocyte Biology. 2001, 69: 307-316.
39. Salmi M, Jalkenen S: How do lymphocytes know where to go: current concepts and enigmas of lymphocyte homing. Advances in Immunology. 1997, 64: 139-218.
40. Shimizu Y, Rose DM, Ginsberg MH: Integrins in the immune system. American Journal of Physiology. 1999, 265: 325-380.
41. Steeber DA, Tedder TF: Adhesion molecule cascades direct lymphocyte recirculation and leukocyte migration during inflammation. Immunologic Research. 2001, 22: 299-317.
42. Simmons D, Makgoba MW, Seed B: ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature. 1988, 331: 624-627.
43. Staunton DE, Marlin SD, Stratowa C, Dustin ML, Springer TA: Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell. 1988, 52: 925-933.
44. Budnik A, Grewe M, Gyufko K, Krutmann J: Analysis of the production of soluble ICAM-1 molecules by human cells. Experimental Hematology. 1996, 24: 352-359.
45. Cartwright JE, Whitley GS, Johnstone AP: The expression and release of adhesion molecules by human endothelial cell lines and their consequent binding of lymphocytes. Experimental Cell Research. 1995, 217: 329-335.
46. Hashimoto M, Shingu M, Ezaki I, Nobunaga M, Minamihara M, Kato K, Sumioki H: Production of soluble ICAM-1 from human endothelial cells induced by IL-1 beta and TNF-alpha. Inflammation. 1994, 18: 163-173.
47. Lyons PD, Benveniste EN: Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease. Glia. 1998, 22: 103-112.
48. Pigott R, Dillon LP, Hemingway IH, Gearing AJ: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochemical and Biophysical Research Communications. 1992, 187: 584-589.
49. Ohh M, Takei F: New insights into the regulation of ICAM-1 gene expression. Leukaemia and Lymphoma. 1996, 20: 223-228.
50. Stolpe Van de A, Saag Van der PT: Intercellular adhesion molecule-1. Journal of Molecular Medicine. 1996, 74: 13-33.
51. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman G, Aruffo A: CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. Journal of Cell Biology. 1995, 128: 687-698.
52. Bourguignon LY: CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. Journal of Mammary Gland Biology and Neoplasia. 2001, 6: 287-297.
53. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Pold M, Batra RK, Dubinett SM: Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. Journal of Biological Chemistry. 2001, 276: 20809-20812.
54. Lin YH, Yang-Yen HF: The osteopontin-Cd44 survival signal involves activation of the phosphatidylinositol-3-kinase/akt signaling pathway. Journal of Biological Chemistry. 2001, 276: 46024-46030.
55. Lisignoli G, Grassi F, Zini N, Toneguzzi S, Piacentini A, Guidolin D, Bevilacqua C, Facchini A: Anti-Fas-induced apoptosis in chondrocytes reduced by hyaluronan: evidence for CD44 and CD54 (intercellular adhesion molecule 1) involvement. Arthritis and Rheumatology. 2001, 44: 1800-1807.
56. Ponta H, Wainwright D, Herrlich P: The CD44 protein family. International Journal of Biochemistry and Cell Biology. 1998, 30: 299-305.
57. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proceedings of the National Academy of Science USA. 1992, 89: 12160-12164.
58. Yasuda M, Tanaka Y, Fujii K, Yasumoto K: CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. International Immunology. 2001, 13: 1309-1319.
59. Yu Q, Stamenkovic I: Localization of matrix metallproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes and Development. 1999, 13: 35-48.
60. Lesley J, Hyman R, Kincade PW: CD44 and its interaction with extracellular matrix. Advances in Immunology. 1993, 54: 271-335.
61. Lesley J, Hyman R, English N, Catterall JB, Turner GA: CD44 in inflammation and metastasis. Glycoconjugate Journal. 1997, 14: 611-622.
62. Entwistle J, Hall CL, Turley EA: HA receptors: regulators of signalling to the cytoskeleton. Journal of Cellular Biochemistry. 1996, 61: 569-577.
63. Hayflick JS, Kilgannon P, Gallitin WM: The intercellular adhesion molecule (ICAM) family of proteins. New members and novel functions. Immunologic Research. 1998, 17: 313-327.
64. Henry SP, Templin MV, Gillett N, Rojko J, Levin AA: Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicologic Pathology. 1999, 27: 95-100.
65. Roebuck KA, Finnegan A: Regulation of intercellular adhesion molecule-1 (CD54) gene expression. Journal of Leukocyte Biology. 1999, 66: 876-888.
66. Watanabe T, Fan J: Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. International Journal of Cardiology. 1998, 66: S45-53.
67. Bajorath J: Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins. 2000, 39: 103-111.
68. Goodison S, Urquidi V, Tarin D: CD44 cell adhesion molecules. Molecular Pathology. 1999, 52: 189-196.
69. Ilangumaran S, Borisch B, Hoessli DC: Signal transduction via CD44: role of plasma membrane microdomains. Leukaemia and Lymphoma. 1999, 35: 455-469.
70. Kincade PW, Zheng Z, Katoh S, Hanson L: The importance of the cellular environment to function of the CD44 matrix receptor. Current Opinion in Cell Biology. 1997, 635-642.
71. Naot D, Sionov RV, Ish-Shalom D: CD44: Structure, function and association with the malignant process. Advances in Cancer Research. 1997, 71: 241-319.
72. Pure E, Cuff CA: A crucial role for CD44 in inflammation. Trends in Molecular Medicine. 2001, 7: 213-221.
73. Wielenga VJM, Neut van der R, Offerhaus GJA, Pals ST: CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value. Advances in Cancer Research. 2000, 77: 169-187.
74. Bosken CH, Doerschuk CM, English D, Hogg JC: Neutrophil kinetics during active cigarette smoking in rabbits. Journal of Applied Physiology. 1991, 71: 630-637.
75. Bosken CH, Hards J, Gatter K, Hogg JC: Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocytochemistry. American Review of Respiratory Diseases. 1992, 145: 91.
76. Bridges AB, Hill A, Belch JJ: Cigarette smoking increases white blood cell aggregation in whole blood. Journal of the Royal Society of Medicine. 1993, 86: 139-140.
77. Dougan PS, Edwards JD, Zhan X, Wilde M, Agrawal DK: Cigarette smoking increases monocyte adherence to cultured endothelial cell monolayer. Biochemical and Biophysical Research Communications. 1994, 203: 929-934.
78. Hunninghake GW, Crystal RG: Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. American Review of Respiratory Diseases. 1983, 128: 833-838.
79. Kalra VK, Ying Y, Deemer K, Natarajan R, Nadler JL, Coates TD: Mechanism of cigarette smoke condensate induced adhesion of human monocytes to cultured endothelial cells. Journal of Cell Physiology. 1994, 160: 154-162.
80. Kilburn KH, McKenzie W: Leukocyte recruitment to airways by cigarette smoke and particle phase in contrast to cytotoxicity of vapor. Science. 1975, 189: 634-637.
81. Klut ME, Doerschuk CM, Van Eeden SF, Burns AR, Hogg JC: Activation of neutrophils within pulmonary microvessels of rabbits exposed to cigarette smoke. American Journal of Respiratory Cell and Molecular Biology. 1993, 9: 82-89.
82. Lehr HA, Kress E, Menger MD, Friedl HP, Hubner C, Arfors KE, Messmer K: Cigarette smoke elicits leukocyte adhesion to endothelium in hamsters: inhibition by CuZn-SOD. Free Radical Biology and Medicine. 1993, 14: 573-581.
83. Lehr HA, Kress E, Menger MD: Involvement of 5-lipoxygenase products in cigarette smoke-induced leukocyte/endothelium interaction in hamsters. International Journal of Microcirculation: Clinical and Experimental. 1993, 12: 61-73.
84. MacNee W, Wiggs B, Belzberg AS, Hogg JC: The effect of cigarette smoking on neutrophil kinetics in human lungs. New England Journal of Medicine. 1989, 321: 924-928.
85. Ricevuti G, Mazzone A, Mazzucchelli I, Fossati G, Pasotti D, Cavigliano P, Rolandi L, Viarengo G, Rossi M, Notario A: Phagocyte activation in coronary artery disease. FEMS Microbiology and Immunology. 1992, 5: 271-278.
86. Rylander R: Pulmonary cell responses to inhaled cigarette smoke. Archives of Environmental Health. 1974, 29: 329-333.
87. Schaberg T, Lauer C, Lode H, Fischer J, Haller H: Increased number of alveolar macrophages expressing adhesion molecules of the leukocyte adhesion molecule family in smoking subjects. Association with cell-binding ability and superoxide anion production. American Review of Respiratory Diseases. 1992, 146: 1287-1293.
88. Weber C, Erl W, Weber K, Weber PC: Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation. 1996, 93: 1488-1492.
89. Terashima T, Klut ME, English D, Hards J, Hogg JC, van Eeden SF: Cigarette smoking causes sequestration of polymorphonuclear leukocytes released from the bone marrow in lung microvessels. American Journal of Respiratory Cell and Molecular Biology. 1999, 20: 171-177.
90. Costabel U, Guzman J: Effect of smoking on bronchoalveolar lavage constituents. European Respiratory Journal. 1992, 5: 776-779.
91. Hoogsteden HC, van Hal PT, Wijkhuijs JM, Hop W, Verkaik AP, Hilvering C: Expression of the CD11/CD18 cell surface adhesion glycoprotein family on alveolar macrophages in smokers and nonsmokers. Chest. 1991, 100: 1567-1571.
92. Schaberg T, Rau M, Oerter R, Liebers U, Rahn W, Kaiser D, Witt C, Lode H: Expression of adhesion molecules in peripheral pulmonary vessels from smokers and nonsmokers. Lung. 1996, 174: 71-81.
93. Lensmar C, Elmberger G, Skold M, Eklund A: Smoking alters the phenotype of macrophages in induced sputum. Respiratory Medicine. 1998, 92: 415-420.
94. Di Stefano A, Maestrelli P, Roggeri A, Turato G, Calabro S, Potena A, Mapp CE, Ciaccia A, Covacev L, Fabbri LM: Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. American Journal of Respiratory and Critical Care Medicine. 1994, 149: 803-810.
95. Hogg JC: Identifying smokers at risk for developing airway obstruction. Chest. 1998, 114: 355.
96. Maestrelli P, Calcagni PG, Saetta M, Bertin T, Mapp CE, Sanna A, Veriter C, Fabbri LM, Stanescu D: Integrin upregulation on sputum neutrophils in smokers with chronic airway obstruction. American Journal of Respiratory and Critical Care Medicine. 1996, 154: 1296-1300.
97. Noguera A, Batle S, Miralles C, Iglesias J, Busquets X, MacNee W, Agusti AGN: Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax. 2001, 56: 432-437.
98. Gonzalez S, Hards J, van Eeden S, Hogg JC: The expression of adhesion molecules in cigarette smoke-induced airways obstruction. European Respiratory Journal. 1996, 9: 1995-2001.
99. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, Okada Y, Yamasawa F, Umeda A: Increased expression of inflammatory mediators in small-airway epithelium from tobacco smokers. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2000, 278: L906-L913.
100. Rusznak C, Mills PR, Devalia JL, Sapsford RJ, Davies RJ, Lozewicz S: Effect of cigarette smoke on the permeability and IL-1beta and sICAM-1 release from cultured human bronchial epithelial cells of never-smokers, smokers, and patients with chronic obstructive pulmonary disease. American Journal of Respiratory Cell and Molecular Biology. 2000, 23: 530-536.
101. Adams MR, Jessup W, Celermajer DS: Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. Journal of the American College of Cardiology. 1997, 29: 491-497.
102. Kevil CG, Patel RP, Bullard DC: Essential role of ICAM-1 in mediating monocyte adhesion to aortic endothelial cells. American Journal of Physiology. 2001, 281: C1442-1447.
103. Russell MA, Jarvis M, Iyer R, Feyerabend C: Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. British Medical Journal. 1980, 280: 972-976.
104. Scott DA, Todd DH, Wilson RF, Coward PY, Odell EW, Poston RN, Matthews JP, Palmer RM: The acute influence of tobacco smoking on adhesion molecule expression on monocytes and neutrophils and on circulating adhesion molecule levels in vivo. Addiction Biology. 2000, 5: 195-205.
105. Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JM, Klebanoff SJ, Waltersdorph A, Wong G, Clark SC, Vadas MA: Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. Journal of Clinical Investigation. 1986, 78: 1220-1228.
106. Spark JI, Scott DJA, Chetter IC, Guillou PJ, Kester RC: Does soluble intercellular adhesion molecule-1 (ICAM-1) affect neutrophil activation and adhesion following ischaemia-reperfusion?. European Journal of Vascular and Endovascular Surgery. 1999, 17: 115-120.
107. Bainton DF, Miller LJ, Kishimoto TK, Springer TA: Leukocyte adhesion receptors are stored in peroxidase-negative granules of human neutrophils. Journal of Experimental Medicine. 1987, 166: 1641-1653.
108. Miller LJ, Bainton DF, Borregaard N, Springer TA: Stimulated mobilization of monocyte Mac-1 and p150,95 adhesion proteins from an intracellular vesicular compartment to the cell surface. Journal of Clinical Investigation. 1987, 80: 535-544.
109. Ryder MI, Fujitaki R, Lebus S, Mahboub M, Faia B, Muhaimin D, Hamada M, Hyun W: Alterations of neutrophil L-selection and CD18 expression by tobacco smoke: implications for periodontal diseases. Journal of Periodontal Research. 1998, 33: 359-368.
110. Selby C, Drost E, Brown D, Howie S, MacNee W: Inhibition of neutrophil adherence and movement by acute cigarette smoke exposure. Experimental Lung Research. 1992, 18: 813-827.
111. Pernerstorfer T, Stohlawetz P, Stummvoll G, Kapiotis S, Szekeres T, Eichler HG, Jilma B: Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. British Journal of Haematology. 1998, 102: 1229-1231.
112. Ismail AI, Bert BA, Ekland SA: Epidemiologic patterns of smoking and periodontal disease in the United States. Journal of the American Dental Association. 1983, 106: 617-621.
113. Machtei EE, Dunford R, Hausmann E, Grossi SG, Powell J, Cummins D, Zambon JJ, Genco RJ: Longitudinal study of prognostic factors in established periodontitis patients. Journal of Clinical Periodontology. 1997, 24: 102-109.
114. Scott DA, Palmer RM, Stapleton JA: Validation of smoking status in clinical research into inflammatory periodontal disease. Journal of Clinical Periodontology. 2001, 28: 715-22.
115. Tomar SL, Asma S: Smoking-attributable periodontitis in the United States: findings from NHANES III. National Health and Nutrition Examination Survey. Journal of Periodontology. 2000, 71: 743-751.
116. Kinane DF, Adonogianaki E, Moughal N, Winstanley FP, Mooney J, Thornhill M: Immunocytochemical characterization of cellular infiltrate, related endothelial changes and determination of GCF acute-phase proteins during human experimental gingivitis. Journal of Periodontal Research. 1991, 26: 286-288.
117. Koundouros E, Odell E, Coward PY, Wilson RF, Palmer RM: Soluble adhesion molecules in serum of smokers and non-smokers, with and without periodontitis. Journal of Periodontal Research. 1996, 31: 596-599.
118. Alavi AL, Palmer RM, Odell EW, Coward PY, Wilson RF: Elastase in gingival crevicular fluid from smokers and non-smokers with chronic inflammatory periodontal disease. Oral Diseases. 1995, 1: 103-105.
119. Pauletto NC, Liede K, Nieminen A, Larjava H, Uitto V-J: Effect of cigarette smoking on oral elastase activity in adult periodontitis patients. Journal of Periodontology. 2000, 71: 58-62.
120. Fors BP, Goodarzi K, von Andrian UH: L-selectin shedding is independent of its subsurface structures and topographic distribution. Journal of Immunology. 2001, 167: 3642-3651.
121. Hafezi-Moghadam A, Thomas KL, Prorock AJ, Huo Y, Ley K: L-selectin shedding regulates leukocyte recruitment. Journal of Experimental Medicine. 2001, 193: 863-872.
122. Bergmann S, Siekmeier R, Mix C, Jaross W: Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respiration Physiology. 1998, 114: 269-275.
123. Blann AD, Steele C, McCollum CN: The influence of smoking on soluble adhesion molecules and endothelial cell markers. Thrombosis Research. 1997, 85: 433-438.
124. Blann AD, Kirkpatrick U, Devine C, Naser S, McCollum CN: The influence of acute smoking on leucocytes, platelets and the endothelium. Atherosclerosis. 1998, 141: 133-139.
125. Fassbender K, Bertsch T, Mielke O, Muhlhauser F, Hennerici M: Adhesion molecules in cerebrovascular diseases. Evidence for an inflammatory endothelial activation in cerebral large-and small-vessel disease. Stroke. 1999, 30: 1647-1650.
126. Grothey A, Heistermann P, Philippou S, Voigtmann R: Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. British Journal of Cancer. 1998, 77: 801-807.
127. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk Communities (ARIC) study. Circulation. 1997, 96: 4219-4225.
128. Noguchi T, Tsujisaki M, Imai K, Dodo M, Tabuchi Y, Nakajima T, Kajita A, Hayashi I, Sugiura T, Kumahara Y: Relationship among risk factors of atherosclerosis, leukocyte count, and soluble intercellular adhesion molecule-1. Internal Medicine. 1998, 37: 123-126.
129. O'Malley T, Ludlam CA, Riemermsa RA, Fox KA: Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1). Potential risk factor for the acute coronary syndromes. European Heart Journal. 2001, 22: 1226-1234.
130. Rohde LE, Lee RT, Rivero J, Jamacochian M, Arroyo LH, Briggs W, Rifai N, Libby P, Creager MA, Ridker PM: Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology. 1998, 18: 1765-1770.
131. Rohde LE, Hennekens CH, Ridker PM: Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arteriosclerosis, Thrombosis and Vascular Biology. 1999, 19: 1595-1599.
132. van Tits LJ, de Waart F, Hak-Lemmers HL, van Heijst P, de Graaf J, Demacker PN, Stalenhoef AF: Effects of alpha-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers. Free Radicals in Biology and Medicine. 2001, 30: 1122-1129.
133. Wallen NH, Held C, Rehnqvist N, Hjemdahl P: Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. European Heart Journal. 1999, 20: 1039-1043.
134. Zoppini G, Targher G, Cacciatori V, Guerriero A, Muggeo M: Chronic cigarette smoking is associated with increased plasma circulating intercellular adhesion molecule 1 levels in young type 1 diabetic patients. Diabetes Care. 1999, 22: 1871-1874.
135. Grigg J, Riedler J, Robertson CF: Soluble intercellular adhesion molecule-1 in the bronchoalveolar lavage fluid of normal children exposed to parental cigarette smoke. European Respiratory Journal. 1999, 13: 810-813.
136. Rumalla A, Herndon B, Pyszczynski D, Suvarna P: Does pulmonary airway inflammation relate to intercellular adhesion molecule (ICAM-1) in bronchoalveolar lavage specimens? A pilot study. Molecular Medicine. 1997, 94: 186-189.
137. Scott DA, Stapleton JA, Coward PY, Wilson RF, Sutherland G, Palmer RM, Gustavsson G: Dramatic decline in circulating intercellular adhesion molecule-1 concentration on quitting tobacco smoking. Blood Cells Molecules and Diseases. 2000, 26: 255-258.
138. Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, Rijcken B, Sawe U: Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. European Respiratory Journal. 1999, 13: 238-246.
139. Kittl EM, Ruckser R, Rech-Weichselbraun I, Hinterberger W, Bauer K: Significant elevation of tumour-associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking. European Journal of Clinical Chemistry and Clinical Biochemistry. 1997, 35: 81-84.
140. Scott DA, Stapleton JA, Wilson RF, Sutherland G, Palmer RM, Coward PY, Gustavsson G, Odell EW, Poston RN: Plasma concentrations of reputed tumor-associated soluble CD44 isoforms (v5 and v6) in smokers are dose-related and decline on smoking cessation. Cancer Epidemiology, Biomarkers and Prevention. 2000, 9: 1211-1214.
141. Blann AD, McCollum CN: Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thrombosis and Haemostasis. 1994, 72: 151-154.
142. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. British Journal of Rheumatology. 1995, 34: 814-819.
143. Ghaisis NK, Chandreshwar NS, Foley B, Goggins M, Crean P, Kelly A, Kelleher D, Walsh M: Elevated levels of circulating soluble adhesion molecules in peripheral blood of patients with unstable angina. American Journal of Cardiology. 1997, 80: 617-619.
144. Morisaki N, Saito I, Tamura K, Tashiro J, Masuda M, Kanzaki T, Watanabe S, Masuda Y, Saito Y: New indices of ischemic heart disease and aging: studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease. Atherosclerosis. 1997, 131: 43-48.
145. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J: Plasma concentration of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998, 351: 88-92.
146. Shyu KG, Chang H, Lin CC, Kuan P: Circulating intercellular adhesion molecule-1 and E-selectin in patients with acute coronary syndrome. Chest. 1996, 109: 1627-1630.
147. Squadrito F, Saitta A, Altavilla D, Ioculano M, Canale P, Campo GM, Squadrito G, Di Tano G, Mazzu A, Caputi AP: Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction. Inflammation Research. 1996, 45: 14-19.
148. Becker A, van Hinsbergh VWM, Jager A, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA: Why is soluble intercellular adhesion molecule-1 related to cardiovascular mortality?. European Journal of Clinical Investigation. 2002, 32: 1-8.
149. Banks RE, Gearing AJH, Hemingway IK, Norfolk DR, Perren TJ, Selby PJ: Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. British Journal of Cancer. 1993, 68: 122-124.
150. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD: Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thombosis and Haemostasis. 1994, 72: 979-984.
151. De Rose V, Oliva A, Messore B, Grosso B, Mollar C, Pozzi E: Circulating adhesion molecules in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 1998, 157: 1234-1239.
152. Goke M, Hoffmann JC, Evers J, Kruger H, Manns MP: Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. Journal of Gastroenterology. 1997, 32: 480-486.
153. Kobayashi T, Hashimoto S, Isma K, Amemiya E, Yamaguchi M, Horie T: Elevation of serum soluble intercellular adhesion molecule-1 (sICAM-1) and sE-selectin levels in bronchial asthma. Clinical and Experimental Immunology. 1994, 96: 110-115.
154. Pforte A, Schiessler A, Gais P, von Kress S, Beer B, Riethmuller G, Ziegler-Heitbrock HW: Expression of the adhesion molecule ICAM-1 on alveolar macrophages and in serum in extrinsic allergic alveolitis. Respiration. 1993, 60: 221-226.
155. Shijubo N, Imai K, Shigehara K, Hirasawa M, Tsujisaki M, Hinoda Y, Abe S: Soluble intercellular adhesion molecule-1 (ICAM-1) in sera and bronchoalveolar lavage (BAL) fluids of extrinsic allergic alveolitis. Clinical and Experimental Immunology. 1995, 102: 91-97.
156. Blann AD, Seigneur M, Steiner M, Miller JP, McCollum CN: Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolaemia: relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events. Thrombosis and Haemostasis. 1998, 79: 1080-1085.
157. Rifai N, Joubran R, Yu H, Asmi M, Jouma M: Inflammatory markers in men with angiographically documented coronary heart disease. Clinical Chemistry. 1999, 45: 1967-1973.
158. Barnett CC, Moore EE, Moore FA, Carl VS, Biffl WL: Soluble ICAM-1 (sICAM-1) provokes PMN elastase release. Journal of Surgical Research. 1996, 63: 6-10.
159. Barnett CC, Moore EE, Moore FA, Biffl WL, Partrick DA: Soluble intercellullar adhesion molecule-1 provokes polymorphonuclear leukocyte elastase release by CD18. Surgery. 1996, 120: 395-402.
160. Barnett CC, Moore EE, Mierau GW, Partrick DA, Biffl WL, Elzi DJ, Silliman CC: ICAM-1-CD18 interaction mediates neutrophil cytotoxicity through protease release. American Journal of Physiology. 1998, 274: C1634-1644.
161. Lukacs NW, Chensue SW, Strieter RM, Warmington K, Kunkel SL: Inflammatory granuloma formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-1. Journal of Immunology. 1994, 152: 5883-5889.
162. McCabe SM, Riddle L, Nakamura GR, Prashad H, Mehta A, Berman PW, Jardieu P: sICAM-1 enhances cytokine production stimulated by alloantigen. Cellular Immunology. 1993, 150: 364-375.
163. Otto VI, Heinzel-Pleines UE, Gloor SM, Trentz O, Kossmann T, Morganti-Kossmann MC: sICAM-1 and TNF-alpha induce MIP-2 with distinct kinetics in astrocytes and brain microvascular endothelial cells. Journal of Neuroscience Research. 2000, 60: 733-742.
164. Schmal H, Czermak BJ, Lentsch AB, Bless NM, Beck-Schimmer B, Friedl HP, Ward PA: Soluble ICAM-1 activates lung macrophages and enhances lung injury. Journal of Immunology. 1998, 161: 3685-3693.
165. Cobb RR, Dubins JS, Warner J, Molony L: Functional expression of soluble ICAM-1 by baculovirus-infected Sf9 cells. Biochemical and Biophysical Research Communications. 1992, 185: 1022-1033.
166. Kusterer K, Bojunga J, Enghofer M, Heidenthal E, Usadel KH, Kolb H, Martin S: Soluble ICAM-1 reduces leukocyte adhesion to vascular endothelium in ischemia-reperfusion injury in mice. American Journal of Physiology. 1998, 275: G377-80.
167. Meyer DM, Dustin ML, Carron CP: Characterization of intercellular adhesion molecule-1 ectodomain (sICAM-1) as an inhibitor of lymphocyte function-associated molecule-1 interaction with ICAM-1. Journal of Immunology. 1995, 155: 3578-3584.
168. Ohno N, Ichikawa H, Coe L, Kvietys PR, Granger DN, Alexander JS: Soluble selectins and ICAM-1 modulate neutrophil-endothelial adhesion and diapedesis in vitro. Inflammation. 1997, 21: 313-324.
169. Rieckmann P, Michel U, Albrecht M, Bruck W, Wockel L, Felgenhauer K: Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. Journal of Neuroimmunology. 1995, 60: 9-1.
170. Altomonte M, Gloghini A, Bertola G, Gasparollo A, Carbone A, Ferrone S, Maio M: Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Research. 1993, 53: 3343-3348.
171. Becker JC, Dummer R, Hartmann AA, Burg G, Schmidt RE: Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. Journal of Immunology. 1991, 147: 4398-4401.
172. Becker JC, Dummer R, Schmidt RE, Burg G, Hartmann AA: Shedding of soluble intercellular adhesion molecule 1 (ICAM-1) from melanoma cells and the effect on cellular cytotoxicity. Immunitat und Infektion. 1992, 20: 62-63.
173. Becker JC, Termeer C, Schmidt RE, Brocker EB: Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. Journal of Immunology. 1993, 151: 7224-7232.
174. Bossu P, Singer GG, Andres P, Ettinger R, Marshak-Rothstein A, Abbas AK: Mature CD4+ T lymphocytes from MRL/lpr mice are resistant to receptor-mediated tolerance and apoptosis. Journal of Immunology. 1993, 151: 7233-7239.
175. Kaihara A, Iwagaki H, Gouchi A, Hizuta A, Isozaki H, Takakura N, Tanaka N: Soluble intercellular adhesion molecule-1 and natural killer cell activity in gastric cancer patients. Research Communications in Molecular Pathology and Pharmacology. 1998, 100: 283-300.
176. Gho YS, Kleinman HK, Sosne G: Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Research. 1999, 59: 5128-5132.
177. Wei W, Kim Y, Boudreau N: Association of smoking with serum and dietary levels of antioxidants in adults: NHANES III, 1988–1994. American Journal of Public Health. 2001, 91: 258-26.
178. Jilma B, Blann AD, Stohlawetz P, Eichler HG, Kautzky-Willer A, Wagner OF: Dexamethasone lowers circulating E-selectin and ICAM-1 in healthy men. Journal of Laboratory and Clinical Medicine. 2000, 135: 270-274.
179. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD: A form of circulating ICAM-1 in human serum. Journal of Immunology. 1991, 147: 3788-3793.
180. Seth R, Raymond FD, Makgoba MW: Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet. 1991, 338: 83-84.
181. Inuzuka H, Seita T, Okamoto K, Iida K, Ogawa Y, Iwasa S: A sensitive ELISA for the characterization of two forms of circulating intercellular adhesion molecule-1 in human plasma. Biological and Pharmaceutical Bulletin. 1995, 18: 1036-1040.
182. Wakatsuki T, Kimura K, Kimura F, Shinomiya N, Ohtsubo M, Ishizawa M, Yamamoto M: A distinct mRNA encoding a soluble form of ICAM-1 molecule expressed in human tissues. Cell Adhesion and Communication. 1995, 3: 283-292.
183. Champagne B, Tremblay P, Cantin A, St Pierre Y: Proteolytic cleavage of ICAM-1 by human neutrophil elastase. Journal of Immunology. 1998, 161: 6398-6405.
184. Miller J, Knorr R, Ferrone M, Houdei R, Carron CP, Dustin ML: Intercellular adhesion molecule-1 dimerization and its consequences for adhesion mediated by lymphocyte function associated-1. Journal of Experimental Medicine. 1995, 182: 1231-1241.
185. Reilly PL, Woska JR, Jeanfavre DD, McNally E, Rothlein R, Bormann BJ: The native structure of intercellular adhesion molecule-1 (ICAM-1) is a dimer. Correlation with binding to LFA-1. Journal of Immunology. 1995, 155: 529-532.
186. Young DG, Jackson AM, James K: Purification and characterisation of soluble intercellular molecule-1 and its effects on cell-mediated cytolysis of bladder tumour cells. Biochemical Society Transactions. 1997, 25: 365S.
187. Carley W, Ligon G, Phan S, Dziuba J, Kelley K, Perry C, Gerritsen ME: Distinct ICAM-1 forms and expression pathways in synovial microvascular endothelial cells. Cellular and Molecular Biology. 1999, 45: 79-88.
188. Diamond MS, Staunton DE, Marlin SD, Springer TA: Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell. 1991, 65: 961-971.
189. Fraser HS, Palmer RM, Wilson RF, Coward PY, Scott DA: Elevated systemic concentrations of soluble ICAM-1 are not reflected in the gingival crevicular fluid of smokers with periodontitis. Journal of Dental Research. 2001, 80: 1643-1647.
190. Scott DA, Coward PY, Wilson RF, Poston RN, Odell EW, Palmer RM: Serum concentration of total soluble CD44 is elevated in smokers. Biomarkers. 2000, 5: 240-254.
191. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS: Potential use of soluble CD44 in serum as an indicator of tumour burden and metastasis in patients with gastric or colon cancer. Cancer Research. 1994, 65: 422-426.
192. Kopp R, Classen S, Wolf H, Gholam P, Possinger K, Wilmanns W: Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Research. 2001, 21: 2995-3000.
193. Martin S, Jansen F, Bokelmann J, Kolb H: Soluble CD44 splice variants in metastasizing human breast cancer. International Journal of Cancer. 1997, 74: 443-445.
194. Ristamaki R, Joensuu H, Lappalainen K, Teerenhovi L, Jalkanen S: Elevated serum CD44 level is associated with unfavourable outcome in non-Hodgkin's lymphoma. Blood. 1997, 90: 4039-4.
195. Ristamaki R, Joensuu H, Gron-Virta K, Salmi M, Jalkanen S: Origin and function of circulating CD44 in non-Hodgkin's lymphoma. Journal of Immunology. 1997, 158: 3000-3008.
196. Ristamaki R, Joensuu H, Jalkanen S: Serum CD44 in non-Hodgkin's Lymphoma. Leukemia and Lymphoma. 1999, 33: 433-440.
197. Sasaki K, Niitsu N: Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma. European Journal of Haematology. 2000, 65: 195-202.
198. Yamane N, Tsujitani S, Makino M, Maeta M, Kaibara N: Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer. Oncology. 1999, 56: 232-238.
199. Haberhauer G, Kittl EM, Skoumal M, Hubl W, Wagner E, Bayer PM, Bauer K, Dunky A: Increased serum levels of soluble CD44-isoform v5 in rheumatic diseases are restricted to seropositive rheumatoid arthritis. Acta Medica Austriaca. 1997, 24: 23-25.
200. Kato S, Matsubara Y, Taniguchi Abe K, Yoshinaga R, Yamashiro S, Mukai H, Kadota J, Kawano S, Matsukura S: Evaluation of soluble CD44 in the BALF before and after treatment of DPB (diffuse panbronchitis) with macrolide antibiotics. Japanese Journal of Antibiotics. 1998, 51: S38-40.
201. Kittl EM, Haberhauer G, Ruckser R, Selleny S, Rech-Weichselbraun I, Hinterberger W, Bauer K: Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis. Rheumatology International. 1997, 16: 181-186.
202. Bourguignon LYW, Gunja-Smith Z, Iida N, Zhu HB, Young LJT, Muller WJ, Cardiff RD: CD44v(3,8–10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. Journal of Cellular Physiology. 1998, 176: 206-215.
203. Granberg D, Wilander E, Oberg K, Skogseid B: Prognostic markers in patients with typical bronchial carcinoid tumors. Journal of Clinical Endocrinology and Metabolism. 2000, 85: 3425-3430.
204. Gunthert U, Hoffman M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991, 65: 13-24.
205. Kuo MY-P, Cheng S-J, Chen H-M, Kok S-H, Hahn L-J, Chiang C-P: Expresion of CD44s, CD44v5, CD44v6 and CD44v7–8 in betel chewing-associated oral premalignant lesions and squamous cell carcinomas in Taiwan. Journal of Oral Pathology and Medicine. 1998, 27: 428-433.
206. Nguyen VN, Mirejovsky T, Melinova L, Mandys V: CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma. 2000, 47: 400-408.
207. Pirinen R, Hirvikoski P, Bohm J, Kellokoski J, Moisio K, Viren M, Johansson R, Hollmen S, Kosma VM: Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Human Pathology. 2000, 3: 1088-1095.
208. Ross JS, Sheehan CE, Williams SS, Malfetano JH, Szyfelbein WM, Kallakury BV: Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. American Journal of Clinical Pathology. 2001, 116: 122-128.
209. Wimmel A, Kogan E, Ramaswamy A, Schuermann M: Variant expression of CD44 in preneoplastic lesions of the lung. Cancer. 2001, 92: 1231-1236.
210. Khaldoyanidi S, Sikora L, Orlovskaya I, Matrosova V, Kozlov V, Sriramarao P: Correlation between nicotine-induced inhibition of hematopoiesis and decreased CD44 expression on bone marrow stromal cells. Blood. 2001, 98: 303-312.
211. Dalchau R, Kirkley J, Fabre JW: Monoclonal antibody to a human brain-granulocyte-T lymphocyte antigen probably homologous to the W 3/13 antigen of the rat. European Journal of Immunology. 1980, 10: 745-749.
212. Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM: Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis and Rheumatology. 1991, 34: 1434-1441.
213. Chiu RK, Carpenito C, Dougherty ST, Hayes GM, Dougherty GJ: Identification and characterization of CD44RC, a novel alternatively spliced soluble CD44 isoform that can potentiate the hyaluronan binding activity of cell surface CD44. Neoplasia. 1999, 1: 446-452.
214. Skelton TP, Zeng C, Nocks A, Stamenkovic I: Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. Journal of Cell Biology. 1998, 140: 431-446.
215. Yu Q, Toole BP, Stamenkovic I: Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. Journal of Experimental Medicine. 1997, 186: 1985-1996.
216. Peterson RM, Yu Q, Stamenkovic I, Toole BP: Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. American Journal of Pathology. 2000, 156: 2159-2167.
217. Ahrens T, Sleeman JP, Schempp CM, Howells N, Hofmann M, Ponta H, Herrlich P, Simon JC: Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene. 2001, 20: 3399-3408.
218. Katoh S, McCarthy JB, Kincade PW: Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumor growth. Journal of Immunology. 1994, 153: 3440-3449.
219. Sy MS, Guo YJ, Stamenkovic I: Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. Journal of Experimental Medicine. 1992, 176: 623-627.
220. Zawadzki V, Perschl A, Rosel M, Hekele A, Zoller M: Blockade of metastasis formation by CD44-receptor globulin. International Journal of Cancer. 1998, 75: 919-924.
221. Thomas L, Byers HR, Vink J, Stamenkovic I: CD44H regulates tumor cell migration on hyaluronate-coated substrate. Journal of Cell Biology. 1992, 118: 971-977.
222. Peter K, Nawroth P, Conradt C, Nordt T, Weiss T, Boehme M, Wunsch A, Allenberg J, Kubler W, Bode C: Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arteriosclerosis Thrombosis and Vascular Biology. 1997, 17: 505-512.
223. Osterud B, Elvevoll EO, Brox J, Anderssen T, Eliassen LT, Halvorsen H, Hogmo P, Kvernmo H, Lia K, Lund T, Olsen JO, Olsen RL, Engstad CS, Vognild E: Haemostatic parameters related to lipids and adhesion molecules. Blood Coagulation and Fibrinolysis. 1999, 10: 465-470.
224. Blann A, Morris J, McCollum C: Soluble L-selectin in peripheral arterial disease: relationship with soluble E-selectin and soluble P-selectin. Atherosclerosis. 1996, 126: 227-231.
225. Blann AD, Goode GK, Miller JP, McCollum CN: Soluble P-selectin in hyperlipidaemia with and without symptomatic vascular disease: relationship with von Willebrand factor. Blood Coagulation and Fibrinolysis. 1997, 8: 200-204.
226. Blann AD, Amiral J, McCollum CN: Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. European Journal of Haematology. 1997, 59: 115-120.
227. Circulating endothelial cell/leucocyte adhesion molecules in ischaemic heart disease. British Journal of Haematology. 1996, 95: 263-265.
228. Blann AD, Noteboom WM, Rosendaal FR: Increased soluble P-selectin levels following deep venous thrombosis: cause or effect?. British Journal of Haematology. 2000, 108: 191-193.
229. Blann AD, Faragher EB, McCollum CN: Increased soluble P-selectin following myocardial infarction: a new marker for the progression of atherosclerosis. Blood Coagulation and Fibrinolysis. 1997, 8: 383-390.
230. Blann AD, Seigneur M, Boisseau MR, Taberner DA, McCollum CN: Soluble P selectin in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease and its risk factors. Blood Coagulation and Fibrinolysis. 1996, 7: 789-793.
231. Kitamura T, Tamada Y, Kato M, Yokochi T, Ikeya T: Soluble E-selectin as a marker of disease activity in pustulosis palmaris et plantaris. Acta Dermatologica Venereologica. 1999, 79: 462-464.